Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) Net Margin (2020 - 2025)

Vivos Therapeutics (VVOS) has disclosed Net Margin for 6 consecutive years, with 79.61% as the latest value for Q3 2025.

  • On a quarterly basis, Net Margin fell 1184.0% to 79.61% in Q3 2025 year-over-year; TTM through Sep 2025 was 98.77%, a 1229.0% decrease, with the full-year FY2024 number at 74.09%, up 2465.0% from a year prior.
  • Net Margin was 79.61% for Q3 2025 at Vivos Therapeutics, up from 131.23% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 44.15% in Q1 2023 to a low of 168.24% in Q4 2021.
  • A 5-year average of 111.36% and a median of 119.95% in 2021 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: skyrocketed 17744bps in 2021, then tumbled -8365bps in 2025.
  • Vivos Therapeutics' Net Margin stood at 168.24% in 2021, then grew by 8bps to 154.15% in 2022, then increased by 14bps to 132.45% in 2023, then surged by 42bps to 76.45% in 2024, then dropped by -4bps to 79.61% in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Net Margin are 79.61% (Q3 2025), 131.23% (Q2 2025), and 128.12% (Q1 2025).